Podcast Episodes
Back to Search
Episode: 89 - James E. Crowe, Jr. on AHEAD 100, a New Strategy for Preparing for the Next Pandemic
Season 2 Episode 89
You can’t forecast the next epidemic with precision, so why do we keep building preparedness plans that depend on guessing? Host Dennis Burton, Ph.D.…
11 hours ago
Episode: 88 - Janice Reichert on the Evolution of Antibody Therapeutics
Season 2 Episode 88
How have antibody trends changed over the decades? Janice Reichert, Ph.D., founder and editor-in-chief of mAbs, joins host Paul Carter, Ph.D., to dis…
1 month ago
Episode: 87 - Jack Elands on How Novel ADC Payloads Could Improve Cancer Care
Season 2 Episode 87
July 14, 2026 | Most ADCs today lean on the same Topo-1 payloads—and resistance is catching up. Jack Elands, Ph.D., founder and CEO of Adcytherix, sp…
2 months ago
Episode: 86 - PANEL DISCUSSION: Near-Term Challenges for ML/AI in Biotherapeutic R&D
Season 2 Episode 86
At this year’s PEGS Boston, industry experts gathered on a panel to explore how AI and machine learning are deployed in biologics R&D today. Moderate…
3 months ago
Episode: 85 - Daniel Chen on Building Multi-Target Drugs with Logic Gating
Season 2 Episode 85
May 12, 2026 | When it comes to drug discovery, either you find a rare, clean target and everything clicks, or you spend a decade chasing biology tha…
4 months ago
Episode: 84 - Martin Pacesa on BindCraft: An Automated Pipeline for De Novo Protein Binder Design
Season 2 Episode 84
How is BindCraft, the automated pipeline for de novo protein binder design, changing the protein design industry? Martin Pacesa, assistant professor …
5 months ago
Episode: 83 - Patrick Baeuerle and Jeffrey Miller on T Cell and Immune Cell Engagement
Season 2 Episode 83
T cell and immune cell engagement is gaining traction, but what makes it different from other therapies? Patrick Baeuerle, Ph.D., chief scientific ad…
5 months, 4 weeks ago
Episode: 82 - PANEL DISCUSSION: Future of Biologic Therapeutics: Will Half-Life Extended Peptides Replace Multispecific Antibodies?
Season 2 Episode 82
During last year’s PEGS Europe, industry experts gathered on a panel to discuss the future of biologic therapeutics. The panel kicked off with a pres…
7 months ago
Episode: 81 - Laszlo Radvanyi on Pushing Boundaries in Cancer Immunotherapy Research
Season 2 Episode 81
How has immunotherapy evolved in the last decade? In this episode of The Chain, Laszlo Radvanyi, professor of immunology at the University of Toronto…
8 months ago
Episode: 80 - Vibha Jawa Discusses the Impact of Biologic Molecules and the Future of Immunogenicity
Season 2 Episode 80
December 13, 2025 | What is next for immunogenicity? In this episode of The Chain, Vibha Jawa, chief scientific officer at EpiVax, provides her thoug…
9 months ago